Comparison · NCT01762761-sae
Eltrombopag vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Eltrombopag vs Placebo: serious adverse events. Trial comparisons, record NCT01762761-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01762761-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.317 | 0.236 | 0.412 | wilson | |
| Risk in group 2 | 0.333 | 0.22 | 0.47 | wilson | |
| Risk difference, group 1 minus group 2 | -0.016 | -0.175 | 0.132 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.952 | 0.589 | 1.54 | log | |
| Odds ratio, group 1 over group 2 | 0.93 | 0.455 | 1.9 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Eltrombopag than on Placebo | 62.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Eltrombopag | Participants initially received eltrombopag 25 mg QD. Based on weekly platelet counts, the dose of eltrombopag was adjusted to maintain platelet counts between 50×10\^9/L and 250×10\^9/L for a period of 8 weeks. | 33 | 104 | EG001 |
| Group 2 | Placebo | Participants initially received placebo QD. Based on weekly platelet counts, the dose of placebo was adjusted to maintain platelet counts between 50×10\^9/L and 250×10\^9/L for a period of 8 weeks. | 17 | 51 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse Event (AE) timeframe: Adverse events were collected from study start (form first dose of study treatment) until end of study treatment plus 30 days post-treatment, up to a maximum duration of approx. 70 months.
Source ClinicalTrials.gov
Trial
- Title
- Eltrombopag Phase III Study In Chinese Chronic ITP Patients
- NCT number
- NCT01762761
- Phases
- PHASE3
- Conditions
- Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
- Interventions
- eltrombopag, placebo
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2015-03-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01762761?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01762761-sae